In letter to Allergan, SEC says it will scrutinize industry's use of non-GAAP accounting
Fierce Pharma | February 13, 2017
When the SEC criticized Valeant Pharmaceuticals over its use of non-GAAP reporting, it seemed like a regulator barking at a company known for pushing the limits. But now the agency has fired a warning shot across the bow of the industry, saying in a letter to Allergan that it intends to examine how the industry is potentially exploiting the practice.